Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 10/20 | 0.51 |
| ▸ | EGFR | P00533 | 8/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18346268 | 0.90 | KDR (0.39) | BTKEGFRABCB11ESR1CHRM2 | |
| SCHEMBL18346354 | 0.88 | ABCB11 (0.38) | BTKEGFRABCB11ESR1CHRM2 | |
| SCHEMBL20211537 | 0.84 | EGFR (0.42) | BTKEGFRABCB11ESR1CHRM2 | |
| SCHEMBL20211521 | 0.82 | FGFR4 (0.38) | BTKEGFRABCB11ESR1CHRM2 | |
| SCHEMBL18346366 | 0.81 | EGFR (0.55) | BTKEGFRABCB11ESR1CHRM2 | |
| SCHEMBL20211543 | 0.80 | JAK3 (0.42) | BTKEGFRJAK3ITK | |
| SCHEMBL20211542 | 0.80 | JAK3 (0.42) | BTKEGFRJAK3ITK | |
| SCHEMBL18345885 | 0.80 | EGFR (0.39) | BTKEGFRABCB11ESR1CHRM2 | |
| SCHEMBL18346272 | 0.80 | IRAK4 (0.41) | BTKKDRJAK3JAK2BLK | |
| SCHEMBL20225395 | 0.79 | CDK7 (0.48) | EGFRJAK3ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10342798-B2 | Fused bicyclic pyrimidine derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10342798-B2 | Fused bicyclic pyrimidine derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20180369243-A9 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-12-27 | — | — | US | disclosed |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| EP-3313529-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | Dana Farber Cancer Institute, Inc. (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210291-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369243-A9 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | CDK3, CDK14, CDK1 | BTK 916/4885EGFR 1810/4885ABCB11 3706/4885 |
| US-10342798-B2 | Fused bicyclic pyrimidine derivatives and uses thereof | CDK3, CDK14, CDK1 | BTK 916/4885EGFR 1810/4885ABCB11 3706/4885 |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | CDK3, CDK14, CDK1 | BTK 916/4885EGFR 1810/4885ABCB11 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.